Published October 21, 2025 | Version v1
Journal article Open

Styrylquinoline derivatives as IGF1R inhibitors

Authors/Creators

  • 1. ROR icon University of Silesia in Katowice
  • 2. ROR icon Silesian University of Technology

Description

Styrylquinoline analogs exhibiting antiproliferative activity against glioblastoma multiforme were tested for tyrosine kinase inhibition. A preliminary SAR analysis based on previous results showed that the styrylquinoline fragment is a promising privileged structure. The addition of appropriate pharmacophores to both the quinoline structure and the benzene ring, which was attached to the 2-position, significantly altered the antiproliferative properties. Namely, OH or NO2 substituents had a positive effect on activity, while F and OAc molecular fragments had a negative impact. Screening conducted on a panel of receptor tyrosine kinases revealed the high potential of the tested compounds for use as IGF1R inhibitors. Molecular docking performed on the IGF1R unphosphorylated inactive conformation confirmed the high binding affinity of the active styrylquinoline derivatives.

Files

Files (185.1 kB)

Name Size Download all
md5:3546b0984f8578117583240774fd53f7
152.7 kB Download
md5:5b66205c2dadf60a752c69e59d7bf978
12.5 kB Download
md5:b439d6759a09c1e0be9708a333ca1e52
19.8 kB Download

Additional details

Funding

National Science Centre
NAWA PRELUDIUM BIS 2020/39/O/NZ5/02342

References

  • Simpson A, Petnga W, Macaulay VM, Weyer-Czernilofsky U, Bogenrieder T: Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. Target Oncol 2017, 12(5):571-597.
  • Li R, Pourpak A, Morris SW: Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem 2009, 52(16):4981-5004.
  • Ma Y, Tang N, Thompson RC, Mobley BC, Clark SW, Sarkaria JN, Wang J: InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Clin Cancer Res 2016, 22(7):1767-1776.
  • Crudden C, Song D, Cismas S, Trocme E, Pasca S, Calin GA, Girnita A, Girnita L: Below the Surface: IGF-1R Therapeutic Targeting and Its Endocytic Journey. Cells 2019, 8(10).
  • Turvey SJ, McPhillie MJ, Kearney MT, Muench SP, Simmons KJ, Fishwick CWG: Recent developments in the structural characterisation of the IR and IGF1R: implications for the design of IR-IGF1R hybrid receptor modulators. RSC Med Chem 2022, 13(4):360-374.
  • Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, O'Connor M, Pirritt C, Sun Y, Yao Y et al: Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2009, 1(6):1153-1171.
  • Luffy M, Ganz AL, Wagner S, Wolf J, Ropertz J, Zeidan R, Kent JD, Douglas RS, Kahaly GJ: Linsitinib inhibits proliferation and induces apoptosis of both IGF-1R and TSH-R expressing cells. Front Immunol 2024, 15:1488220.
  • Boutin A, Eliseeva E, Templin S, Marcus-Samuels B, Anderson DE, Gershengorn MC, Neumann S: Linsitinib Decreases Thyrotropin-Induced Thyroid Hormone Synthesis by Inhibiting Crosstalk Between Thyroid-Stimulating Hormone and Insulin-Like Growth Factor 1 Receptors in Human Thyrocytes In Vitro and In Vivo in Mice. Thyroid 2025, 35(2):216-224.
  • Tognon CE, Sorensen PH: Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin Ther Targets 2012, 16(1):33-48.
  • Xia Y, Jin L, Zhang B, Xue H, Li Q, Xu Y: The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sci 2007, 80(23):2161-2169.
  • Waraky A, Akopyan K, Parrow V, Stromberg T, Axelson M, Abrahmsen L, Lindqvist A, Larsson O, Aleem E: Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via insulin-like growth factor-1 receptor-independent mechanism. Oncotarget 2014, 5(18):8379-8392.
  • Bao XH, Naomoto Y, Hao HF, Watanabe N, Sakurama K, Noma K, Motoki T, Tomono Y, Fukazawa T, Shirakawa Y et al: IGF-IR and its inhibitors in gastrointestinal carcinomas (Review). Oncol Lett 2010, 1(1):195-201.
  • Bergqvist M, Holgersson G, Bondarenko I, Grechanaya E, Maximovich A, Andor G, Klockare M, Thureson M, Jerling M, Harmenberg J: Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer. Acta Oncol 2017, 56(3):441-447.
  • Szczepaniak J, Cieslik W, Romanowicz A, Musiol R, Krasowska A: Blocking and dislocation of Candida albicans Cdr1p transporter by styrylquinolines. Int J Antimicrob Agents 2017, 50(2):171-176.
  • Musiol R, Jampilek J, Buchta V, Silva L, Niedbala H, Podeszwa B, Palka A, Majerz-Maniecka K, Oleksyn B, Polanski J: Antifungal properties of new series of quinoline derivatives. Bioorg Med Chem 2006, 14(10):3592-3598.
  • Musiol R: Styrylquinoline - A Versatile Scaffold in Medicinal Chemistry. Med Chem 2020, 16(2):141-154.
  • Malarz K, Mularski J, Kuczak M, Mrozek-Wilczkiewicz A, Musiol R: Novel Benzenesulfonate Scaffolds with a High Anticancer Activity and G2/M Cell Cycle Arrest. Cancers (Basel) 2021, 13(8).
  • Mrozek-Wilczkiewicz A, Spaczynska E, Malarz K, Cieslik W, Rams-Baron M, Krystof V, Musiol R: Design, Synthesis and In Vitro Activity of Anticancer Styrylquinolines. The p53 Independent Mechanism of Action. Plos One 2015, 10(11):e0142678.
  • Mrozek-Wilczkiewicz A, Kuczak M, Malarz K, Cieslik W, Spaczynska E, Musiol R: The synthesis and anticancer activity of 2-styrylquinoline derivatives. A p53 independent mechanism of action. Eur J Med Chem 2019, 177:338-349.
  • Papaconstantinou J: Insulin/IGF-1 and ROS signaling pathway cross-talk in aging and longevity determination. Mol Cell Endocrinol 2009, 299(1):89-100.
  • El-Sayed MA, El-Husseiny WM, Abdel-Aziz NI, El-Azab AS, Abuelizz HA, Abdel-Aziz AA: Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study. J Enzyme Inhib Med Chem 2018, 33(1):199-209.
  • Mularski J, Malarz K, Pacholczyk M, Musiol R: The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series. Eur J Med Chem 2019, 163:610-625.
  • Malarz K, Kuczak M, Rurka P, Rawicka P, Boguszewska-Czubara A, Jampilek J, Mularski J, Musiol R, Mrozek-Wilczkiewicz A: Unveiling the role of Ndrg1 gene on the oxidative stress induction behind the anticancer potential of styrylquinazoline derivatives. Sci Rep 2025, 15(1):16081.
  • Malarz K, Mularski J, Pacholczyk M, Musiol R: Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations. J Enzyme Inhib Med Chem 2023, 38(1):2201410.
  • Moriev R, Vasylchenko O, Platonov M, Grygorenko O, Volkova K, Zozulya S: Identification of Novel IGF1R Kinase Inhibitors by Molecular Modeling and High-Throughput Screening. Acta Naturae 2013, 5(2):90-99.
  • Fan C, Huang YX, Bao YL, Sun LG, Wu Y, Yu CL, Zhang Y, Song ZB, Zheng LH, Sun Y et al: Virtual screening of specific insulin-like growth factor 1 receptor (IGF1R) inhibitors from the National Cancer Institute (NCI) molecular database. Int J Mol Sci 2012, 13(12):17185-17209.
  • Kuczak M, Cieslik W, Musiol R, Mrozek-Wilczkiewicz A: 4-Furanylvinylquinoline derivative as a new scaffold for the design of oxidative stress initiator and glucose transporter inhibitor drugs. Sci Rep 2024, 14(1):28454.